Selective prospective studies of intensive frontline therapies in newly diagnosed MCL
| Phase . | Induction . | Consolidation . | N . | OR (CR), % . | Median response . | Median OS . | TRM . | Reference . |
|---|---|---|---|---|---|---|---|---|
| II (Single Centre) | R-Hyper-CVAD | — | 97 | 97 (87) | 22% 15 years FFS | 33% 15 years | 8% | Chihara et al1 |
| II (Multi Centre) | R-Hyper-CVAD | — | 60 | 83 (72) | 61% 5 years PFS | 73% 5 years | 6.50% | Merli et al6 |
| II (Multi Centre) | R-Hyper-CVAD | — | 49 | (86 (55) | 4.8 years PFS | 6.8 years | 2% | Bernstein et al7 |
| III (Randomized) | R-CHOP | Dexa BEAM ASCT | 455 | 98 (63) | 3.8 years PFS | 6.8 years | 4% | Hermine et al5 |
| vs | vs | vs | vs | |||||
| R-CHOP/R-DHAP | ASCT | 99 (61) | 7.3 years PFS | NR | ||||
| III (Randomized) | R-DHAP | ASCT | 299 | 74% 3 years PFS | 85% 3 years OS | NA | Le Gouill et al16 | |
| vs | vs | vs | vs | |||||
| ASCT + rituximab maintenance | 88% 3 years PFS | 93 3 years OS | ||||||
| II (Multi Centre) | R-Maxi-CHOP + HD AraC | ASCT | 160 | 96 (54) | 7.4 years EFS | 70% 6 years | 5% | Geisler et al8 |
| II (Multi Centre) | R-CHOP/R-DHAP | ASCT | 60 | 100 (96) | 7 years EFS | 75% 5 years | 1.50% | Delarue et al2 |
| II (Multi Centre) | R-Maxi-CHOP + HD AraC | ASCT + RIT if not CR | 160 | 97 (82) | 71% 4 years PFS | 78% 4 years OS | 3% | Kolstad et al11 |
| II (2 Centre) | RB/HD AraC | ASCT | 23 | 96 (96) | 96% 1 year PFS | 96% 1 year OS | 0% | Armand et al14 |
| Phase . | Induction . | Consolidation . | N . | OR (CR), % . | Median response . | Median OS . | TRM . | Reference . |
|---|---|---|---|---|---|---|---|---|
| II (Single Centre) | R-Hyper-CVAD | — | 97 | 97 (87) | 22% 15 years FFS | 33% 15 years | 8% | Chihara et al1 |
| II (Multi Centre) | R-Hyper-CVAD | — | 60 | 83 (72) | 61% 5 years PFS | 73% 5 years | 6.50% | Merli et al6 |
| II (Multi Centre) | R-Hyper-CVAD | — | 49 | (86 (55) | 4.8 years PFS | 6.8 years | 2% | Bernstein et al7 |
| III (Randomized) | R-CHOP | Dexa BEAM ASCT | 455 | 98 (63) | 3.8 years PFS | 6.8 years | 4% | Hermine et al5 |
| vs | vs | vs | vs | |||||
| R-CHOP/R-DHAP | ASCT | 99 (61) | 7.3 years PFS | NR | ||||
| III (Randomized) | R-DHAP | ASCT | 299 | 74% 3 years PFS | 85% 3 years OS | NA | Le Gouill et al16 | |
| vs | vs | vs | vs | |||||
| ASCT + rituximab maintenance | 88% 3 years PFS | 93 3 years OS | ||||||
| II (Multi Centre) | R-Maxi-CHOP + HD AraC | ASCT | 160 | 96 (54) | 7.4 years EFS | 70% 6 years | 5% | Geisler et al8 |
| II (Multi Centre) | R-CHOP/R-DHAP | ASCT | 60 | 100 (96) | 7 years EFS | 75% 5 years | 1.50% | Delarue et al2 |
| II (Multi Centre) | R-Maxi-CHOP + HD AraC | ASCT + RIT if not CR | 160 | 97 (82) | 71% 4 years PFS | 78% 4 years OS | 3% | Kolstad et al11 |
| II (2 Centre) | RB/HD AraC | ASCT | 23 | 96 (96) | 96% 1 year PFS | 96% 1 year OS | 0% | Armand et al14 |
ASCT, autologous stem cell transplant; BEAM, BCNU, etoposide, cytarabine, melphalan; FFS, failure-free survival; N, number of patients; HD-AraC, high-dose cytarabine; MTX, methotrexate; NA, not available; NR, not reached; RB, rituximab and bendamustine; R-CHOP, rituximab, cyclophosphamide, vincristine, doxorubicin, prednisolone; R-DHAP, rituximab, dexamethasone, cytarabine, cisplatin; R-Hyper-CVAD, rituximab fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate/cytarabine; TRM, treatment-related mortality.